Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 The penetration of dapsone, rifampicin, isoniazid and pyrazinamide into peripheral nerves.

Literature DB >> 1182342

The penetration of dapsone, rifampicin, isoniazid and pyrazinamide into peripheral nerves.

B W Allen, G A Ellard, P T Gammon, R C King, A C McDougall, R J Rees, A G Weddell.

Abstract

1 Dapsone, rifampicin, isoniazid and pyrazinamide were shown to penetrate readily into the sciatic nerves of the dog and sheep. 2 These findings suggest that the continued persistence of viable drug-sensitive leprosy bacilli in the peripheral nerves of patients treated for long periods with either dapsone or rifampicin is not due to inadequate intraneural drug penetration.

Entities: Chemical Species

Mesh：

Substances：

Year: 1975 PMID： 1182342 PMCID： PMC1666712 DOI： 10.1111/j.1476-5381.1975.tb07623.x

Source DB: PubMed Journal: Br J Pharmacol ISSN： 0007-1188 Impact factor: 8.739

28 in total

1. A study of the renal clearances, metabolic inactivation rates, and serum fall-off interaction of isoniazid and paraminosalicylic acid in man.

Authors: J W JENNE; F M MACDONALD; E MENDOZA
Journal: Am Rev Respir Dis Date: 1961-09

2. Studies on the metabolism of isoniazid. l. Development and application of a fluorometric procedure for measuring isoniazid in blood.

Authors: J H PETERS
Journal: Am Rev Respir Dis Date: 1960-04

3. The ultrafiltrable calcium of human serum. I. Ultrafiltration methods and normal values.

Authors: T Y TORIBARA; A R TEREPKA; P A DEWEY
Journal: J Clin Invest Date: 1957-05 Impact factor: 14.808

4. Ten years of dapsone in lepromatous leprosy: clinical, bacteriological and histological assessment and the finding of viable leprosy bacilli.

Authors: M F Waters; R J Rees; A C McDougall; A G Weddell
Journal: Lepr Rev Date: 1974-12 Impact factor: 0.537

The penetration of dapsone, rifampicin, isoniazid and pyrazinamide into peripheral nerves.

1. A study of the renal clearances, metabolic inactivation rates, and serum fall-off interaction of isoniazid and paraminosalicylic acid in man.

2. Studies on the metabolism of isoniazid. l. Development and application of a fluorometric procedure for measuring isoniazid in blood.

3. The ultrafiltrable calcium of human serum. I. Ultrafiltration methods and normal values.

4. Ten years of dapsone in lepromatous leprosy: clinical, bacteriological and histological assessment and the finding of viable leprosy bacilli.

5. Further experience with the rapid bactericidal effect of rifampin on Mycobacterium leprae.

6. Binding of rifampicin by human plasma proteins.

7. Pyrazinamide and other drugs in tuberculous meningitis.

8. Studies on the metabolic basis for the genetically determined capacities for isoniazid inactivation in man.

9. Assay of rifampicin in serum.

10. The effect of pulsed exposures to rifampin on the uptake of uridine- 14 C by Mycobacterium tuberculosis.

1. Studies on the early changes in acute isoniazid neuropathy in the rat.

Review 2. Clinical pharmacokinetics of dapsone.

Review 3. Clinical pharmacokinetic considerations in the treatment of patients with leprosy.

Review 4. Neurological manifestations and toxicities of the antituberculosis drugs. A review.

Review 5. Clinical pharmacokinetics of isoniazid.

6. Morphometric evaluation of degenerative and regenerative changes in isoniazid-induced neuropathy.

7. Early detection of rifampin in human nerve tissue after an oral dose of 600 milligrams.